New Triple-Drug cocktail aims to beat tough breast cancer
NCT ID NCT07471815
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a combination of camrelizumab (an immunotherapy), risedronate (a bone drug), and chemotherapy in 30 women with triple-negative breast cancer. The goal is to see if adding risedronate can help overcome resistance to standard treatment and improve tumor shrinkage. Researchers will also monitor side effects and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab (immune checkpoint inhibitor) plus risedronate sodium (bisphosphonate) plus chemotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for triple-negative breast cancer by overcoming drug resistance and improving response rates.
- What could go wrong
- This is a small, early-phase exploratory study with only 30 participants, so results may not apply broadly. The combination may cause side effects and may not prove more effective than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 158100, China